Juno Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
May 03 2016 - 3:05PM
Business Wire
Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it
will webcast its presentation at the Bank of America Merrill Lynch
2016 Health Care Conference at 8:40 a.m. Pacific Time (PT) on
Tuesday, May 10, 2016. The presentation will feature a business
overview and update by Steve Harr, Juno’s Chief Financial Officer
and Head of Corporate Development.
The webcast will be accessible on the Investor Relations page of
Juno's website at www.JunoTherapeutics.com. A replay of the
presentation will be available at the same location for 30 days
following the conference.
About Juno
Juno Therapeutics is building a fully integrated
biopharmaceutical company focused on re-engaging the body’s immune
system to revolutionize the treatment of cancer. Founded on the
vision that the use of human cells as therapeutic entities will
drive one of the next important phases in medicine, Juno is
developing cell-based cancer immunotherapies based on chimeric
antigen receptor and high-affinity T cell receptor technologies to
genetically engineer T cells to recognize and kill cancer. Juno is
developing multiple cell-based product candidates to treat a
variety of B-cell malignancies as well as solid tumors. Several
product candidates have shown compelling clinical responses in
clinical trials in refractory leukemia and lymphoma conducted to
date. Juno's long-term aim is to leverage its cell-based platform
to develop new product candidates that address a broader range of
cancers and human diseases. Juno brings together innovative
technologies from some of the world's leading research
institutions, including the Fred Hutchinson Cancer Research
Center, Memorial Sloan Kettering Cancer Center, Seattle
Children's Research Institute, and The National Cancer
Institute. Juno Therapeutics has an exclusive license to the St.
Jude Children’s Research Hospital patented technology for CD19
directed product candidates that use 4-1BB, which was developed by
Dario Campana, Chihaya Imai, and St. Jude Children’s Research
Hospital.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, Section 27A of the Securities Act of 1933, and Section 21E of
the Securities Exchange Act of 1934, including statements regarding
Juno’s mission, progress, and business plans, Juno’s participation
in the Bank of America Merrill Lynch 2016 Health Care Conference,
and the subject matter of Juno's presentation at that conference.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from such
forward-looking statements, and reported results should not be
considered as an indication of future performance. These risks and
uncertainties include, but are not limited to, risks associated
with: the success, cost, and timing of Juno's product development
activities and clinical trials; Juno's ability to obtain regulatory
approval for and to commercialize its product candidates; Juno's
ability to establish a commercially-viable manufacturing process
and manufacturing infrastructure; regulatory requirements and
regulatory developments; success of Juno's competitors with respect
to competing treatments and technologies; Juno's dependence on
third-party collaborators and other contractors in Juno's research
and development activities, including for the conduct of clinical
trials and the manufacture of Juno's product candidates; Juno's
dependence on Celgene for the development and commercialization
outside of North America and China of Juno’s CD19 product
candidates and any other product candidates for which Celgene
exercises an option; Juno’s dependence on JW Biotechnology
(Shanghai) Co., Ltd, over which Juno does not exercise complete
control, for the development and commercialization of product
candidates in China; Juno's ability to obtain, maintain, or protect
intellectual property rights related to its product
candidates; amongst others. For a further description of the
risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well
as risks relating to Juno's business in general, see Juno's Annual
Report on Form 10-K filed with the Securities and Exchange
Commission on February 29, 2016 and Juno’s other periodic reports
filed with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. Juno
disclaims any obligation to update these forward-looking
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160503006844/en/
Investor Relations:Juno Therapeutics, Inc.Nicole Keith,
206-566-5521nikki.keith@junotherapeutics.comorMedia:W2O GroupJulie Normart,
415-946-1087jnormart@w2ogroup.com
JUNO THERAPEUTICS, INC. (NASDAQ:JUNO)
Historical Stock Chart
From Apr 2024 to May 2024
JUNO THERAPEUTICS, INC. (NASDAQ:JUNO)
Historical Stock Chart
From May 2023 to May 2024